Follow us

Maximilian Kücking advises on complex patent litigation proceedings and technology related issues.

Maximilian Kücking advises clients in the fields of high tech, life sciences and biotechnology on intellectual property issues. He focuses on advising on patent and technology law issues as well as advising and representing clients in complex patent infringement proceedings.

Maximilian has particular expertise in advising on disputes involving complex technologies such as, i.a., semiconductor technology, telecommunications systems, LEDs, network communications, medical devices, and pharmaceuticals. In addition, he is experienced in handling competition disputes, corporate transactions involving intellectual property and information technologies, and national and international trademark and design enforcement.


Maximilian Kücking graduated from the Humboldt University of Berlin with a focus on Intellectual Property. During his legal clerkship, he worked for another international law firm in the field of patent and utility model infringement proceedings as well as for an international law firm in Tokyo.

Prior to joining Herbert Smith Freehills, Maximilian worked for a leading international law firm. He advises in German and English and has a basic knowledge of Japanese.

Experience & expertise

Selected matters

  • a multinational technology company in relation to the enforcement of its patent portfolio
  • a U.S. biopharmaceutical company in connection with patents related to medical diagnostics
  • a South Korean technology company in the enforcement of standard essential patents (SEPs) against a global smartphone manufacturer before the Mannheim District Court*
  • a Japanese consumer electronics manufacturer in several German patent infringement cases against leading mobile device and smartphone manufacturers. The disputes included parallel patent infringement proceedings in the U.S. and patent invalidity proceedings in Germany*
  • a leading U.S. pharmaceutical company on infringement of patents for therapeutic antibody drugs*

*Prior to joining Herbert Smith Freehills